Compare Merck & Co., Inc. (MRK) vs MasTec Inc (MTZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs MasTec Inc — how do they compare? Merck & Co., Inc. trades at $148.15 (market cap $366.28B), while MasTec Inc trades at $240.92 (market cap $19.77B). The key difference: Merck & Co., Inc. is far larger — about 18.5× MasTec Inc's market cap, and Merck & Co., Inc. pays a 2.29% dividend while MasTec Inc pays none. Which is the better fit depends on your goals.
| MRK | MTZ | |
|---|---|---|
Market Cap | $366.28B | $19.77B |
Sector | Health | Technology |
52-Week High | $156.43 | $437.51 |
52-Week Low | $77.60 | $189.18 |
Enterprise Value | $413.04B | $22.69B |
Dividend Yield | 2.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MRK trades at $148.49, down 1.23% on the day, with a bullish technical signal from moving averages and support near $147. The company reported strong earnings beats in recent quarters, with Q3 2026 EPS expected at $2.22. Revenue reached $65.01B in 2025, and the acquisition of Terns Pharmaceuticals aims to bolster its oncology pipeline.
Outlook remains positive with a consensus price target of $157, offering ~6% upside. Risks include high P/E of 118.77 and competitive pressures in pharma. Institutional buying and a 67.57% buy rating from analysts support a constructive view, though net income margin of 4.77% warrants monitoring.
MasTec (MTZ) trades at $246.18, up 3.79% today, with strong analyst support (88.9% buy ratings) and a consensus price target of $436.50. The stock shows bearish technical signals but benefits from record $21.4B backlog and AI infrastructure exposure. Recent Q2 2026 earnings missed expectations slightly, though revenue grew 23% year-over-year. The company raised its 2026 outlook, highlighting expanding data center capabilities and power delivery growth.
MTZ presents a growth opportunity driven by infrastructure demand and AI-linked projects, but faces risks from premium valuation (P/E 39.2), weak cash flow trends, and communications segment softness. Investors should weigh strong institutional interest against execution challenges in a competitive market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About MasTec Inc
MasTec, Inc. is a leading infrastructure construction company operating mainly in North America. The company's services cover a diverse range of end-markets, including communications (building fiber and wireless infrastructure), oil & gas, electric power (transmission, distribution, and clean energy), and industrial projects. MTZ provides critical engineering, procurement, and construction (EPC) services that support the expansion and maintenance of essential infrastructure across the continent.
Read more on MTZ →
